全球最小殘留病檢測市場研究報告-2023-2030 年行業分析、規模、份額、增長、趨勢和預測

全球對微小殘留病檢測市場的需求將從 2022 年的 61.1 億美元增長到 2030 年的近 402.4 億美元，複合年增長率為 26.57%，預計 2023-2030 年研究期間將達到

微小殘留病檢測是一種用於檢測治療後殘留在體內的少量癌細胞的方法。 MRD 測試可以幫助監測癌症治療的有效性並預測復發的可能性。 MRD 檢測的目標是儘早檢測癌細胞，當它們仍處於低水平且尚未形成可見腫瘤時。

市場動態：

癌症發病率的增加推動了對 MRD 檢測的需求。 隨著癌症患者人數的不斷增加，越來越多的患者被診斷出癌症並接受治療，從而增加了對 MRD 檢測的需求。 患者和醫療保健專業人員對 MRD 檢測意識的提高也推動了市場增長。 此外，政府對癌症研究和新癌症治療方法的支持也推動了 MRD 檢測市場的增長。 與此同時，用於 MRD 檢查的新敏感技術的開發正在推動市場增長。 然而，測試的成本和可用性可能會限制市場增長。

研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還可以對全球微小殘留病檢測市場的每個細分市場進行全面評估。 微小殘留病檢測行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

本部分按國家/地區提供詳細的細分數據，以幫助您確定每種產品/服務的目標受眾和未來商機。

按癌症類型

• 流式細胞儀
• 聚合□鍊式反應 (PCR)
• 下一代測序 (NGS)
• 其他

技術

• 血液系統惡性腫瘤（淋巴瘤、白血病）
• 實體癌

按最終用途

• 醫院和專科診所
• 診斷實驗室
• 學術和研究機構
• 其他

按地區分析：

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲對微小殘留病檢測市場當前和未來的需求。 此外，它還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 最小殘留疾病檢測市場的主要參與者是 Exact Sciences Corporation、Grail LLC、Veracyte Inc.、Natera Inc.、Guardant Health、F. Hoffmann-La Roche Ltd、Foundation Medicine Inc.、Qiagen、mdxhealth、Bio-Techne。 本節概述了競爭格局，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。 我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

• 本報告的內容
  • 目的
  • 目標受眾
  • 獨特的銷售建議 (USP) 和提供的服務
• 調查範圍
• 調查方法
  • 市場調研過程
  • 市場研究方法

第 2 章執行摘要

• 市場亮點
• 全球市場概況

第 3 章最小殘留病檢測 - 行業分析

• 簡介 - 市場動態
• 市場驅動因素
• 市場製約因素
• 市場機會
• 行業趨勢
• 波特的五力分析
• 市場吸引力分析
  • 按癌症類型進行市場吸引力分析
  • 按技術進行市場吸引力分析
  • 市場吸引力分析：按最終用途
  • 市場吸引力分析：按地區

第四章價值鏈分析

• 價值鏈分析
• 原材料分析
  • 成分錶
  • 原材料製造商列表
  • 主要原材料價格走勢
• 潛在買家名單
• 營銷渠道
  • 直接營銷
  • 間接營銷
  • 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章微量殘留病檢測的全球市場分析：癌症類型

• 癌症類型總結
• 實際數據和預測數據
• 按癌症類型分析
• 流式細胞儀
• 聚合□鍊式反應 (PCR)
• 下一代測序 (NGS)
• 其他

第 7 章全球最小殘留病檢測市場分析：按技術分類

• 技術概述
• 實際數據和預測數據
• 技術分析
• 血液系統惡性腫瘤（淋巴瘤、白血病）
• 實體瘤

第 8 章最小殘留病檢測的全球市場銷售分析：按最終用途

• 按最終用途匯總
• 實際數據和預測數據
• 最終用途分析
• 醫院和專科診所
• 診斷實驗室
• 學術和研究機構
• 其他

第 9 章微量殘留病檢測的全球市場銷售分析：按地區

• 按地區進行的銷售前景分析
• 介紹銷售分析
• 北美銷售分析
  • 概覽、歷史和預測銷售分析
  • 北美各部門的銷售分析
  • 北美銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 按細分市場進行的歐洲銷售分析
  • 按國家/地區劃分的歐洲銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 意大利銷售分析
  • 俄羅斯銷售分析
  • 其他歐洲銷售分析
• 亞太地區銷售分析
  • 概覽、歷史和未來銷售分析
  • 亞太地區各部門的銷售分析
  • 亞太國家/地區銷售分析
  • 在中國的銷售分析
  • 印度銷售分析
  • 日本的銷售分析
  • 韓國銷售分析
  • 澳大利亞銷售分析
  • 其他亞太地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 拉丁美洲各部門的銷售分析
  • 拉丁美洲國家/地區的銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利的銷售分析
  • 其他拉丁美洲銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 中東/非洲地區的銷售分析
  • 中東和非洲國家/地區的銷售分析
  • 沙特阿拉伯銷售分析
  • 阿聯酋銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 其他中東和非洲銷售分析

第10章微小殘留病檢測企業競爭狀況

• 最小殘留病檢測市場競爭
• 夥伴關係、合作、協議
• 併購
• 新產品發布
• 其他發展

第11章公司簡介

• 前 10 名公司的市場份額分析
• 市場集中度
• 精確科學公司
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期發展狀況
• 聖杯有限責任公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Veracyte 公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Natera 公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 守護健康
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• F. Hoffmann-La Roche Ltd.
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Foundation Medicine Inc.
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 恰根
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• mdx 健康
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 生物技術
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

The global demand for Minimal Residual Disease Testing Market is presumed to reach the market size of nearly USD 40.24 BN by 2030 from USD 6.11 BN in 2022 with a CAGR of 26.57% under the study period 2023 - 2030.

Minimal residual disease testing is a method used to detect small amounts of cancer cells remaining in the body after treatment. MRD testing is used to monitor the effectiveness of cancer treatment and to help predict the likelihood of relapse. The goal of MRD testing is to detect cancer cells at the earliest possible stage when they are still at a low level and have not yet formed a visible tumour. 

Market Dynamics:

The increasing incidence of cancer is driving demand for MRD testing. As cancer cases continue to rise, more patients are being diagnosed and treated for cancer, which is increasing the demand for MRD testing. The growing awareness about MRD testing among patients and healthcare professionals is also driving growth in the market. Furthermore, government support for cancer research and the developing of new cancer therapies is driving growth in the MRD testing market. Along with this, developing new and more sensitive technologies for MRD testing is driving growth in the market. However, the cost and availability of the test may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of minimal residual disease testing. The growth and trends of minimal residual disease testing industry provide a holistic approach to this study. 

Market Segmentation:

This section of the minimal residual disease testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Cancer Type

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

By Technology

• Hematological Malignancy (Lymphoma, Leukemia)
• Solid Tumors

By End-Use

• Hospitals And Specialty Clinics
• Diagnostic Laboratories
• Academic And Research Institutes
• Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Minimal Residual Disease Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the minimal residual disease testing market include Exact Sciences Corporation, Grail LLC, Veracyte Inc., Natera Inc., Guardant Health, F. Hoffmann-La Roche Ltd, Foundation Medicine Inc., Qiagen, mdxhealth, Bio-Techne. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . MINIMAL RESIDUAL DISEASE TESTING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Cancer Type
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By End-Use
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY CANCER TYPE

• 6.1 Overview by Cancer Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Cancer Type
• 6.4 Flow Cytometry Historic and Forecast Sales by Regions
• 6.5 Polymerase Chain Reaction (PCR) Historic and Forecast Sales by Regions
• 6.6 Next Generation Sequencing (NGS) Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY TECHNOLOGY

• 7.1 Overview by Technology
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Technology
• 7.4 Hematological Malignancy (Lymphoma, Leukemia) Historic and Forecast Sales by Regions
• 7.5 Solid Tumors Historic and Forecast Sales by Regions

8 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY END-USE

• 8.1 Overview by End-Use
• 8.2 Historical and Forecast Data
• 8.3 Analysis by End-Use
• 8.4 Hospitals And Specialty Clinics Historic and Forecast Sales by Regions
• 8.5 Diagnostic Laboratories Historic and Forecast Sales by Regions
• 8.6 Academic And Research Institutes Historic and Forecast Sales by Regions
• 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE MINIMAL RESIDUAL DISEASE TESTING COMPANIES

• 10.1. Minimal Residual Disease Testing Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF MINIMAL RESIDUAL DISEASE TESTING INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Exact Sciences Corporation
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. Grail LLC
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Veracyte Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Natera Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Guardant Health
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. F. Hoffmann-La Roche Ltd
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Foundation Medicine Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Qiagen
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. mdxhealth
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Bio-Techne
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Cancer Type (USD MN)
• Flow Cytometry Market Sales by Geography (USD MN)
• Polymerase Chain Reaction (PCR) Market Sales by Geography (USD MN)
• Next Generation Sequencing (NGS) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Technology (USD MN)
• Hematological Malignancy (Lymphoma, Leukemia) Market Sales by Geography (USD MN)
• Solid Tumors Market Sales by Geography (USD MN)
• Analysis by End-Use (USD MN)
• Hospitals And Specialty Clinics Market Sales by Geography (USD MN)
• Diagnostic Laboratories Market Sales by Geography (USD MN)
• Academic And Research Institutes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Minimal Residual Disease Testing Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Minimal Residual Disease Testing Report
• Market Research Process
• Market Research Methodology
• Global Minimal Residual Disease Testing Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Cancer Type
• Market Attractiveness Analysis by Technology
• Market Attractiveness Analysis by End-Use
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Cancer Type (USD MN)
• Flow Cytometry Market Sales by Geography (USD MN)
• Polymerase Chain Reaction (PCR) Market Sales by Geography (USD MN)
• Next Generation Sequencing (NGS) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Technology (USD MN)
• Hematological Malignancy (Lymphoma, Leukemia) Market Sales by Geography (USD MN)
• Solid Tumors Market Sales by Geography (USD MN)
• Global Market Analysis by End-Use (USD MN)
• Hospitals And Specialty Clinics Market Sales by Geography (USD MN)
• Diagnostic Laboratories Market Sales by Geography (USD MN)
• Academic And Research Institutes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.